SCHEMBL20116552

SCHEMBL20116552

CCOc1ccc(I)nc1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.40
MAPT P10636 3/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 4/20 0.38
MAPK1 P28482 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
HPGD P15428 3/20 0.37
TSHR P16473 2/20 0.37
ALDH1A1 P00352 3/20 0.35
LMNA P02545 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CALM1 P0DP23 1/20 0.35
KMT2A Q03164 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
S1PR1 P21453 1/20 0.34
S1PR3 Q99500 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1850824 0.85 KDM4E (0.40) KDM4EMAPTGAAHSD17B10MAPK1
SCHEMBL16741129 0.84 KMT2A (0.33) KMT2A
SCHEMBL441334 0.82 KMT2A (0.39) KDM4EMAPTGAAMAPK1ALDH1A1
SCHEMBL20116553 0.79 KDM4E (0.51) KDM4EMAPTGAAHSD17B10MAPK1
SCHEMBL23167115 0.78 APP (0.50) SMN1; SMN2NPC1RAB9A
SCHEMBL3579306 0.78 SMN1; SMN2 (0.44) KDM4EMAPTGAAHSD17B10MAPK1
SCHEMBL27361645 0.78 MAPT (0.40) KDM4EMAPTGAAHSD17B10MAPK1
SCHEMBL25283191 0.76 LMNA (0.33) LMNA
SCHEMBL9140861 0.76 KDM4E (0.39) KDM4EMAPTGAAHSD17B10MAPK1
SCHEMBL15596189 0.76 HPGD (0.42) KDM4EMAPTHSD17B10MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 KDM4E 2853/4885MAPT 22/4885GAA 67/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 KDM4E 2853/4885MAPT 22/4885GAA 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.